Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DMV1SOR)

• Drug Name: AVP-786 Drug Info

Indication

Disease Entry	ICD 11	Status	REF
Alzheimer disease	8A20	Phase 3	[1]
Neurobehavioral disorder	8A00-8A0Z	Phase 2	[2]
Schizophrenia	6A20	Phase 2	[1]
Pain	MG30-MG3Z	Phase 1	[3]

• Cross-matching ID:
  PubChem CID: 25052519
  CAS Number: CAS 1079043-55-2
  TTD Drug ID: DMV1SOR

Molecule-Related Drug Atlas

Drug(s) Targeting Serotonin transporter (SERT)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Acetaminophen	DMUIE76	Allergic rhinitis	CA08.0	Approved	[4]
Amitriptyline	DMK7F9S	Depression	6A70-6A7Z	Approved	[5]
Fluoxetine	DM3PD2C	Bipolar depression		Approved	[6]
Vortioxetine	DM6F1PU	Major depressive disorder	6A70.3	Approved	[7]
Sertraline	DM0FB1J	Coronary heart disease	BA80.Z	Approved	[8]
Cocaine	DMSOX7I	Anaesthesia	9A78.6	Approved	[9]
Bupropion	DM5PCS7	Depression	6A70-6A7Z	Approved	[10]
Citalopram	DM2G9AE	Acute coronary syndrome	BA41	Approved	[6]
Nortriptyline	DM4KDYJ	Depression	6A70-6A7Z	Approved	[6]
Trazodone	DMK1GBJ	Depression	6A70-6A7Z	Approved	[6]

Drug(s) Targeting Opioid receptor sigma 1 (OPRS1)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Dextromethorphan	DMUDJZM	Allergic rhinitis	CA08.0	Approved	[11]
Dextromethorphan Polistirex	DMEHCY5	Dry cough	MD12	Approved	[6]
CM-2395	DMASPWR	Schizophrenia	6A20	Phase 3	[12]
ADX N05	DMLBYRA	Mood disorder	6A60-6E23	Phase 3	[13]
Igmesine	DMH97XA	Major depressive disorder	6A70.3	Phase 2	[14]
OPC-14523	DMB1WF3	Bulimia nervosa	6B81	Phase 2	[15]
ANAVEX 2-73	DM67OU4	Alzheimer disease	8A20	Phase 1	[16]
SSR-125047	DMSUFW6	Schizophrenia	6A20	Phase 1	[17]
SA-5845	DM6XZRL	Central nervous system disease	8A04-8D87	Phase 1	[18]
SSR-125329A	DMG6NI8	Immune System disease	4A01-4B41	Phase 1	[19]

Molecular Interaction Atlas of This Drug

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
Opioid receptor sigma 1 (OPRS1)	TT5TPI6	SGMR1_HUMAN	Modulator	[3]
Serotonin transporter (SERT)	TT3ROYC	SC6A4_HUMAN	Modulator	[3]

References

• [1] Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
• [2] Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
• [3] Antitussives and substance abuse. Subst Abuse Rehabil. 2013 Nov 6;4:75-82.
• [4] Augmentation effect of combination therapy of aripiprazole and antidepressants on forced swimming test in mice. Psychopharmacology (Berl). 2009 Sep;206(1):97-107.
• [5] Treatment of comorbid pain with serotonin norepinephrine reuptake inhibitors. CNS Spectr. 2008 Jul;13(7 Suppl 11):22-6.
• [6] Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services.
• [7] Radium 223 dichloride for prostate cancer treatment. Drug Des Devel Ther. 2017 Sep 6;11:2643-2651.
• [8] Psychopharmacological treatment of dermatological patients--when simply talking does not help. J Dtsch Dermatol Ges. 2007 Dec;5(12):1101-6.
• [9] Differential involvement of the norepinephrine, serotonin and dopamine reuptake transporter proteins in cocaine-induced taste aversion. Pharmacol Biochem Behav. 2009 Jul;93(1):75-81.
• [10] Clinically relevant drug interactions with new generation antidepressants and antipsychotics. Ther Umsch. 2009 Jun;66(6):485-92.
• [11] Dextromethorphan/quinidine: AVP 923, dextromethorphan/cytochrome P450-2D6 inhibitor, quinidine/dextromethorphan. Drugs R D. 2005;6(3):174-7.
• [12] Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800031127)
• [13] Clinical pipeline report, company report or official report of SK BioPhamaceuticals.
• [14] Antiamnesic and neuroprotective effects of donepezil against learning impairments induced in mice by exposure to carbon monoxide gas. J Pharmacol Exp Ther. 2006 Jun;317(3):1307-19.
• [15] Antidepressant-like responses to the combined sigma and 5-HT1A receptor agonist OPC-14523. Neuropharmacology. 2001 Dec;41(8):976-88.
• [16] 2011 Pipeline of Anavex.
• [17] The pipeline and future of drug development in schizophrenia. Mol Psychiatry. 2007 Oct;12(10):904-22.
• [18] Tumor imaging with 2 sigma-receptor ligands, 18F-FE-SA5845 and 11C-SA4503: a feasibility study. J Nucl Med. 2004 Nov;45(11):1939-45.
• [19] SSR125329A, a high affinity sigma receptor ligand with potent anti-inflammatory properties. Eur J Pharmacol. 2002 Dec 5;456(1-3):123-31.